Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form 4

PROVECTUS BIOPHARMACEUTICALS, INC.

Form 4

Common

Stock

February 28, 2014

FORM	14										APPROVAL		
Washington, D.C. 20549							OMB Number:	3235-0287					
Check the if no lon						Expires:	January 31						
subject t Section Form 4 o	o 16.	SECURITIES									2005 stimated average rden hours per sponse 0.5		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940													
(Print or Type	Respons	ses)											
1. Name and Address of Reporting Person * SCOTT TIMOTHY PHD			2. Issuer Name and Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer						
				PROVECTUS BIOPHARMACEUTICALS, INC. [PVCT]					(Check all applicable)				
(Last)	(F	irst) (Middle)	3. Date of Earliest Transaction ZOfficer (give below)					0% Owner ther (specify				
(Month/Day/Year) President 7327 OAK RIDGE HWY., SUITE A 02/26/2014													
					4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line)				
KNOXVILLE, TN 37931					, , , , , , , , , , , , , , , , , , ,				_X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(St	tate)	(Zip)	Tab	le I - Non-I	Derivative S	ecurit	ies Acq	uired, Disposed o	of, or Benefic	ially Owned		
1.Title of Security (Instr. 3)	ecurity (Month/Day/Year) Execution		Date, if	3. Transaction Code (Instr. 8)	4. Securitie or(A) or Disp (Instr. 3, 4 a	osed o		Securities Compensation of Com	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common	02/26	10014			Code V	Amount	(D)	Price \$		T	401/1 \ 1		
Stock	02/26	5/2014			M	300,000	A	\$ 1.1	300,000	I	401(k) plan		
Common Stock									55,996	I	Family Limited Partnership		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not (9-02)

1,399,970

D

Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form 4

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount of Number of Shares
Stock Option (right to buy)	\$ 1.1	02/26/2014		M	300,000	02/26/2004	02/26/2014	Common Stock	300,000

Reporting Owners

Reporting Owner Name / Address	Relati	onships	

Director 10% Owner Officer Other

SCOTT TIMOTHY PHD 7327 OAK RIDGE HWY. **SUITE A** KNOXVILLE, TN 37931

President

Signatures

/s/ Timothy 02/28/2014 Scott

**Signature of Date Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2